QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer

The investigators plan to initiate a prospective, multicenter, phase II study, recruiting 80 patients with advanced pancreatic cancer who have not received prior treatment. This study aims to enhance the anti-tumor immune effect through the combination of QL1706+Lenvatinib+AG regimen, thereby improving the prognosis of patients with advanced metastatic pancreatic cancer.

Trial Details

NCT ID
NCT07110064
Phase
PHASE2
Sponsor
Du Juan
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • QL1706+Lenvatinib+AG Regimen
Locations (sample)
  • Nanjing, China|32.06167,118.77778

Key Eligibility Criteria

  • a. Age ≥18 years, ECOG performance status ≤2, and expected survival of ≥3 months.
  • b. Patients with histologically or cytologically confirmed advanced metastatic pancreatic cancer.
  • c. At least one measurable lesion according to RECIST 1.1 criteria;
  • d. No prior anti-tumor treatment of any kind.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →